Glucagon-Like Peptide-1 Promotes Islet Cell Growth and Inhibits Apoptosis in Zucker Diabetic Rats
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
A constant remodeling of islet cell mass mediated by proliferative and apoptotic stimuli ensures a dynamic response to a changing demand for insulin. In this study, we investigated the effect of glucagon-like peptide-1 (GLP-1) in Zucker diabetic rats, an animal model in which the onset of diabetes occurs when the proliferative potential and the rate of β-cell apoptosis no longer compensate for the increased demand for insulin. We subjected diabetic rats to a 2-d infusion of GLP-1 and tested their response to an ip glucose tolerance test. GLP-1 produced a significant increase of insulin secretion, which was paralleled by a decrease in plasma glucose levels (P < 0.001 and P < 0.01, respectively). Four days after the removal of the infusion pumps, rats were killed and the pancreas harvested to study the mechanism by which GLP-1 ameliorated glucose tolerance. Ex vivo immunostaining with the marker of cell proliferation, Ki-67, showed that the metabolic changes observed in rats treated with GLP-1 were associated with an increase in cell proliferation of the endocrine and exocrine component of the pancreas. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling staining, a marker of cellular apoptosis, indicated a reduction of apoptotic cells within the islet as well in the exocrine pancreas in GLP-1-treated rats. Double immunostaining for the apoptotic marker caspase-3 and for insulin showed a significant reduction of caspase-3 expression and an increase in insulin content in GLP-1-treated animals. Finally, staining of pancreatic sections with the nuclear dye 4,6-Diaminidino-2-phenyl-dihydrochloride demonstrated a marked reduction of fragmented nuclei in the islet cells of rats treated with GLP-1. Our findings provide evidence that the beneficial effects of GLP-1 in Zucker diabetic rats is mediated by an increase in islet cell proliferation and a decrease of cellular apoptosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [17]
Citations
Cites
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Pick, A., Clark, J., Kubstrup, C., Levisetti, M., Pugh, W., Bonner-Weir, S., & Polonsky, K. S. (1998) · Diabetes · doi:10.2337/diabetes.47.3.358 · Cited by 551
FEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528
Perfetti, R. (2000) · Endocrinology · doi:10.1210/en.141.12.4600 · Cited by 442
Self-citationApoptosis Participates in the Remodeling of the Endocrine Pancreas in the Neonatal Rat
Scaglia, L. (1997) · Endocrinology · doi:10.1210/en.138.4.1736 · Cited by 418
β-Cell Mass Dynamics in Zucker Diabetic Fatty Rats
Finegood, D. T., McArthur, M. D., Kojwang, D., Thomas, M. J., Topp, B. G., Leonard, T., & Buckingham, R. E. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1021 · Cited by 374
Research works printed but not linked: 2
- Nauck, 1993, Normalization of fasting hyperglycemia by exogenous glucagon-like peptide-1 [7–36 amide] in type 2 (non-insulin dependent) diabetic patients, Diabetologia, 36, 741, 10.1007/BF00401145 · DOI · Paper page
- Weibel, 1978, Stereologic methods. In: Practical methods for biologic morphometry, London: Academic Press; vol, 1, 101
Cited by
Items 301–400 of 505
QSAR studies on pyrrolidine amides derivatives as DPP-IV inhibitors for type 2 diabetes
Yang, X., Li, M., Su, Q., Wu, M., Gu, T., & Lu, W. (2013) · Medicinal Chemistry Research · doi:10.1007/s00044-013-0527-2 · Cited by 17
“…mRMR–SFB–SVR DPP-IV inhibitors Introduction Type 2 diabetes (T2D) known as non-insulin-dependent diabetes mellitus (NIDDM) or adult onset diabetes is caused by pancreas b-cell dysfunction deficiency in insulin secretion (Farilla, 2002), insulin resistance, or increased hepatic glucose production.”
BackgroundA perspective on pancreatic stem/progenitor cells
Habener, J. F. (2004) · Pediatric Diabetes · doi:10.1111/j.1399-543x.2004.00077.x · Cited by 17
Wright, S. W., Ammirati, M. J., Andrews, K., Brodeur, A. M., Danley, D. E., Doran, S. D., Lillquist, J. S., Liu, S., McClure, L. D., McPherson, R. K., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.07.081 · Cited by 17
Infante, M., Silvestri, F., Padilla, N., Pacifici, F., Pastore, D., Pinheiro, M. M., Caprio, M., Tesauro, M., Fabbri, A., Novelli, G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041303 · Cited by 20
“…[5–7 It is also interesting to note that animal studies have shown that GLP-1 and GLP-1 RAs can expand beta-cell mass by reducing beta-cell apoptosis and stimulating beta-cell proliferation and beta-cell neogenesis (differentiation of beta cells from ductal progenitor cells) [85–88].”
Takahashi, Y., Kamata, A., Nishimura, M., & Nishihira, J. (2021) · Food & Function · doi:10.1039/d1fo00592h · Cited by 16
Protection of pancreatic β-cells against glucotoxicity by short-term treatment with GLP-1
Park, S.-H., Park, J., Shim, H. M., Na, A., Bae, K.-C., Lim, J.-G., & Song, D. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.139 · Cited by 20
Role of CCN5 ( WNT1 inducible signaling pathway protein 2) in pancreatic islets
Liu, J., Kaddour, N., Chowdhury, S., Li, Q., & Gao, Z. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12507 · Cited by 18
“Growth factors such as HGF and GLP-1 have the potential to accelerate β-cell expansion.(5,6,23) Interestingly, the association of CCN proteins with cell adhesion”
BackgroundSiba, I. P., Bortolanza, M., Vital, M. A. B. F., Andreatini, R., da Cunha, J. M., Bel, E. A. D., & Zanoveli, J. M. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.03.008 · Cited by 18
“Since GLP-1 stimulates the proliferation and preservation of pancreatic beta-cells [68,69], it is plausible to hypothesize that the hypoglycemic effect of fish oil may be related to augment of GLP-1.”
Shukla, A., & Srinivasan, B. P. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.07.012 · Cited by 24
Gao, H., Zhao, Q., Song, Z., Yang, Z., Wu, Y., Tang, S., Alahdal, M., Zhang, Y., & Jin, L. (2017) · The FASEB Journal · doi:10.1096/fj.201700002r · Cited by 15
“GLP-1 can also increase b-cell mass by stimulating b-cell proliferation and inhibiting apoptosis (4, 5).”
BackgroundJeong, J., Yook, S., Jung, Y., Im, B.-H., Lee, M., Ahn, C., Lee, D. Y., & Byun, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.029 · Cited by 16
Vedtofte, L., Bödvarsdóttir, T., Gotfredsen, C. F., Karlsen, A. E., Knudsen, L. B., & Heller, R. S. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.12.005 · Cited by 17
Srivastava, S., Pandey, H. K., Singh, S. K., & Tripathi, Y. B. (2019) · BioScience Trends · doi:10.5582/bst.2019.01181 · Cited by 15
Bohman, S., Waern, I., Andersson, A., & King, A. (2007) · Cell Transplantation · doi:10.3727/000000007783464452 · Cited by 17
Zhang, J., Xue, C., Zhu, T., Vivekanandan, A., Pennathur, S., Ma, Z. A., & Chen, Y. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083509 · Cited by 17
Drug discovery approaches targeting the incretin pathway
Deng, X., Tavallaie, M. S., Sun, R., Wang, J., Cai, Q., Shen, J., Lei, S., Fu, L., & Jiang, F. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103810 · Cited by 15
Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes
Prato, S. D. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01439.x · Cited by 16
Moon, J. H., Choe, H. J., & Lim, S. K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14221 · Cited by 15
“Moreover, GLP-1 receptor activation has demonstrated protective effects against b -cell apoptosis 67,68 .”
BackgroundLuo, X., Pan, L., Nie, A., Wang, Q., Gu, Y., Li, F., Zhang, H., Li, W., & Li, X. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12061 · Cited by 14
“Glucagon-like peptide-1 can inhibit apoptosis of freshly isolated islets in humans(17)and Zucker diabetic fat (ZDF) rats.(18)The anti-inflammatory actions of GLP-1 were also observed in human islets or in cultured beta cells.”
BackgroundSynthesis and Biological Evaluation of Xanthine Derivatives on Dipeptidyl Peptidase 4
Lin, K., Cai, Z., Wang, F., Zhang, W., & Zhou, W. (2013) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c12-01046 · Cited by 14
Yang, H., Wang, S., Ye, Y., Xie, M., Li, Y., Jin, H., Li, J., & Gao, L. (2020) · Neuropeptides · doi:10.1016/j.npep.2020.102110 · Cited by 15
Exenatide: Its position in the treatment of type 2 diabetes
Guerci, B., & Martin, C. S. (2008) · Annales d Endocrinologie · doi:10.1016/j.ando.2008.03.004 · Cited by 14
Hou, G., Li, C.-N., Liu, S., Huan, Y., Liu, Q., Sun, S., Li, L., Hou, S.-C., & Shen, Z. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.010 · Cited by 14
Nauck, M. A., & Vardarli, I. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00004.x · Cited by 12
Hu, H., Xu, M., Qi, R., Wang, Y., Wang, C., Liu, J., Luo, L., Xia, L., & Fang, Z. (2015) · PubMed · Cited by 13
Inhibition of Dipeptidyl Peptidase 4 (DPP IV) Activity by Some Indonesia Edible Plants
Amin, M. S., Saputri, F. C., & Mun’im, A. (2019) · Pharmacognosy Journal · doi:10.5530/pj.2019.11.36 · Cited by 17
Biology and therapeutic potential of GLP-1 in the treatment of diabetes
Chia, C. W., & Egan, J. M. (2005) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2005.08.013 · Cited by 14
What Are Incretins, and How Will They Influence the Management of Type 2 Diabetes?
Bonde, L., Rosenstock, J., & Triplitt, C. L. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.s7-a.1 · Cited by 13
“Two gastrointestinal peptides have been identified as incretins: glucose-dependent insulinotropic peptide (GIP) and GLP-1.”
BackgroundInfluentialSomeya, Y., Tahara, A., Nakano, R., Matsuyama‐Yokono, A., Nagase, I., Fukunaga, Y., Takasu, T., Hayakawa, M., & Shibasaki, M. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0277-8 · Cited by 13
“Moreover, animal studies suggest that chronic exposure to GLP-1 may increase β-cell mass by promoting growth and differentiation while inhibiting apoptosis ( Farilla et al. 2002 ).”
BackgroundNutrient regulation of pancreatic β-cell function in diabetes: problems and potential solutions
Flatt, P. R., & Green, B. D. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340774 · Cited by 14
A Novel Stepwise Differentiation of Functional Pancreatic Exocrine Cells from Embryonic Stem Cells
Shirasawa, S., Yoshie, S., Yokoyama, T., Tomotsune, D., Yue, F., & Sasaki, K. (2010) · Stem Cells and Development · doi:10.1089/scd.2010.0185 · Cited by 12
“GLP-1 is associated with increased cell proliferation of both the endocrine and the exocrine component of the pancreas [28].”
BackgroundSun, T., Zhang, B., Ru, Q., Chen, X., & Lv, B.-D. (2021) · Pharmaceutical Biology · doi:10.1080/13880209.2021.1916542 · Cited by 12
Vickers, S. P., Cheetham, S. C., Birmingham, G. D., Rowley, H. L., Headland, K. R., Dickinson, K., Grempler, R., Hocher, B., Mark, M., & Klein, T. (2012) · Clinical Laboratory · doi:10.7754/clin.lab.2011.110919 · Cited by 15
“In addition, reports have suggested that GLP-1 may have a role in islet neogenesis, differentiation, and the concomitant regulation of β cell mass and preservation [13,14].”
BackgroundChang, F., Cho, C. H.-H., Shen, C., Chien, C.-Y., Ting, L.-W., Lee, M., & Shen, C. (2016) · Cell Transplantation · doi:10.3727/096368916x691439 · Cited by 13
Practical and Economical Approach to Synthesize Sitagliptin
Lin, K., Cai, Z., & Zhou, W. (2013) · Synthetic Communications · doi:10.1080/00397911.2013.773353 · Cited by 12
Üçkaya, G., Delagrange, P., Chavanieu, A., Grassy, G., Berthault, M., Ktorza, A., Cerasi, E., Leibowitz, G., & Kaiser, Ν. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.05818 · Cited by 12
“This is in variance with other animal models in which the anorectic effect of GLP-1 was associated with reduced body weight ( Farilla et al. 2002, Tourrel et al. 2002, Chang et al. 2003).”
ResultAndrén‐Sandberg, Å., & Hardt, P. D. (2005) · PubMed · Cited by 18
Plasticité anatomique et fonctionnelle des cellules β du pancréas endocrine et diabète de type 2
Cerasi, E., & Ktorza, A. (2007) · médecine/sciences · doi:10.1051/medsci/20072310885 · Cited by 17
“Ce dernier effet est relayé à la fois par l’augmentation de l’expression de facteurs de survie de la cellule β comme Akt/PKB ou la p44MAPK et la diminution de celle de protéines proapoptotiques comme les caspases [48].”
BackgroundBeta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
Kassem, L. S., Rajpal, A., Barreiro, M. V. E., & Ismail‐Beigi, F. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13446 · Cited by 17
“127,128 In 2004, Degn et al reported that a short (1-week) treatment with liraglutide improved proinsulin-to-insulin ratio, HOMA-B, first-phase insulin response to glucose, and DI.”
BackgroundIncretin hormones and beta-cell mass expansion: what we know and what is missing?
Tortosa, F., & Dotta, F. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2013.795175 · Cited by 10
Suetomi, R., Ohta, Y., Akiyama, M., Matsumura, T., Taguchi, A., Yamamoto, K., Kamatani, T., & Tanizawa, Y. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13218 · Cited by 9
Liu, L., Wang, Y., Wang, L., Lin, Y., Liu, X., Liu, X., & Liu, L. (2012) · Endocrine Research · doi:10.3109/07435800.2012.713423 · Cited by 11
“GLP-1 inhibited apoptosis through the GLP-1 receptor, which could be prevented by blocking the GLP-1 receptor or interfering with its expression (18).”
BackgroundCrutchlow, M. F., Yu, M. D., Bae, Y., Deng, S. L., & Stoffers, D. A. (2008) · Transplantation Proceedings · doi:10.1016/j.transproceed.2008.03.161 · Cited by 13
“They promote pancreatic -cell ass through proliferative and cytoprotective mechanisms, nd potently enhance -cell function.(5,16,31,32,49) We have lso observed a beneficial effect of one of these agents, xendin-4 (Ex-4), on islet vascularity in intrauterine rowth-retarded (IUGR) rats (J.”
BackgroundPharmacology of GLP-1-based therapies
Holst, J. J. (2008) · The British Journal of Diabetes · doi:10.1177/1474651408100523 · Cited by 12
Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis
Lee, J. M., Yoo, I. K., Lee, J. M., Kim, S. H., Choi, H. S., Kim, E. S., Keum, B., Seo, Y. S., Jeen, Y. T., Chun, H. J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6231-y · Cited by 11
Gene Therapy for Type 1 Diabetes: Is it Ready for the Clinic?
D’Anneo, A., Rood, P. P. M., Bottino, R., Balamurugan, A. N., He, J., & Giannoukakis, N. (2006) · Immunologic Research · doi:10.1385/ir:36:1:83 · Cited by 14
“For other factors, like PAX4 (57), HGF (58), IGF-1 (59,60), or GLP-1 (61), the insulin promoter should be used to construct the cassettes eventually introduced into the vector.”
BackgroundIs Facilitating Pancreatic Beta Cell Regeneration a Valid Option for Clinical Therapy?
Trucco, M. (2006) · Cell Transplantation · doi:10.3727/000000006783982322 · Cited by 13
Haluzík, M., Mráz, M., & Svacina, S. (2014) · Drug Safety · doi:10.1007/s40264-014-0238-8 · Cited by 10
“Studies have also documented that GLP-1 stimulates b-cell proliferation and neogenesis and inhibits b-cell apoptosis in both normal and diabetic rodents of younger age [49, 50], Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies”
BackgroundVMP1-related autophagy induced by a fructose-rich diet in β-cells: its prevention by incretins
Maiztegui, B., Boggio, V., Román, C. L., Flores, L. E., Zotto, H. H. D., Ropolo, A., Grasso, D., Vaccaro, M. I., & Gagliardino, J. J. (2017) · Clinical Science · doi:10.1042/cs20170010 · Cited by 12
Matsuyama‐Yokono, A., Tahara, A., Nakano, R., Someya, Y., Hayakawa, M., & Shibasaki, M. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0348-x · Cited by 10
“…Astellas Pharma Inc., 5-2-3, Toukoudai, Tsukuba, Ibaraki, 300-2698, Japan e-mail: akiko.matsuyama@jp.astellas.com duodenal homeobox-1, insulin, etc.), trophic effects on beta cells, inhibition of food intake, and the slowing of gastric emptying (Holst and Deacon 2004; Farilla et al. 2002).”
BackgroundProtective Role of Glucagon-Like Peptide-1 Against High-Glucose-Induced Endothelial Oxidative Damage
Guo, L., Qiao, Y., Zhang, L., & Pan, Q. (2015) · Medicine · doi:10.1097/md.0000000000002055 · Cited by 11
“D-glucose, GLP-1(7-36), MTT, and collagenase I were purchased from Sigma Aldrich (Shanghai, China).”
MethodVildagliptin ameliorates renal injury in type 2 diabetic rats by suppressing oxidative stress
Aghahoseini, F., Alihemmati, A., Hosseini, L., & Badalzadeh, R. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00548-7 · Cited by 12
“In experimental studies, continuous infusion of GLP-1 or long-term injections of GLP-1mimetics such as exendin-4 has had significant effects on reducing glucose levels and enhancing beta-cell neogenesis, decreasing apoptosis, and secreting glucagon from alpha cells [7, 8].”
BackgroundInvestigational agents that protect pancreatic islet β-cells from failure
Aston‐Mourney, K., Proietto, J., & Andrikopoulos, S. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.10.1241 · Cited by 11
“The treatment of animal models of Type 2 diabetes, such as the Goto–Kakizaki (GK), the db/db diabetic mouse and the Zucker diabetic fatty (ZDF) rat, with GLP-1 has been associated with increased β-cell mass and protection from apoptosis [80-82] Furthermore, GLP-1 agonists and inhibitors of DPP-IV have been shown to pr…”
MethodGiorgino, F., Natalicchio, A., Leonardini, A., & Laviola, L. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.09.022 · Cited by 11
Signals Arising from the Gastrointestinal Tract that Affect Food Intake
Purhonen, A. (2008) · Cited by 10
A review of the last decade: pancreatic cancer and type 2 diabetes
Wu, J., Tang, L., Zheng, F., Chen, X., & Li, L. (2023) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2023.2252204 · Cited by 9
“…some studies, like the one conducted by wang et al. , have not found a significant link between incretin drug use and pancreatic cancer risk, other research and animal models have suggested potential associations (Farilla et al. 2002, Butler et al. 2013, Azoulay et al. 2016, wang et al. 2018).”
Effect of glucagon-like peptide-1 gene expression on graft function in mouse islet transplantation
Chae, H. Y., Kang, J. G., Kim, C. S., Lee, S. J., Lee, M., Kang, D., Jun, H., & Ihm, S. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01394.x · Cited by 9
“In addition to its insulinotropic effects on glucose metabolism by stimulating b-cells, GLP1 acts as a growth factor for b-cells, increasing the b-cell mass via the proliferation of islet cells, neogenesis and differentiation of pancreatic ductal cells into insulin-producing cells, while inhibiting b-cell apoptosis [1…”
BackgroundKim, W. J., Park, C., Jeong, E. H., Seo, J. Y., Seol, J. S., Park, S. E., Rhee, E., Lee, W., Oh, K. W., Park, S. W., et al. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.3.290 · Cited by 9
“The use of a glucagon suppressing hormone from α-cells [4] has resulted in significant improvements of differentiation and proliferation of β-cells and inhibition of apoptosis in animal model and human islets [5,6].”
BackgroundLi, D., Zou, H., Yin, P., Li, W., He, J., Wang, S., Huang, L., Shao, S., Chen, Y., Yang, Y., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14217 · Cited by 11
Perioperative Considerations for Patients on Semaglutide
Pai, S., Smith, M. A., Beam, W. B., & Harbell, M. W. (2024) · Current anesthesiology reports · doi:10.1007/s40140-024-00611-6 · Cited by 10
“GLP-1 is also known to slow the gastrointestinal tract, decrease appetite, suppress glucagon, and prevent β-cell apoptosis [18, 19].”
GLP-1 signaling and the regulation of pancreatic β-cells mass/function
Buteau, J. (2011) · Avances en Diabetología · doi:10.1016/s1134-3230(11)70002-3 · Cited by 14
A new therapeutic class for the therapy of type 2 diabetes: DPP-4 inhibitors (sitagliptin)
Ábel, T., & Fehér, J. (2010) · Orvosi Hetilap · doi:10.1556/oh.2010.28910 · Cited by 9
Stabilizing effect of exenatide in a patient with C‐peptide‐negative diabetes mellitus
Paisley, A. N., Savage, M. W., & Wiles, P. G. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02789.x · Cited by 8
Metformina: más allá del control glucémico
de Colombia, U. N., Morantes-Caballero, J. A., Londoño-Zapata, G. A., de Colombia, U. N., Rivera, M. R., de Colombia, U. N., Pinilla-Roa, A. E., & de Colombia, U. N. (2017) · Revista Médicas UIS · doi:10.18273/revmed.v30n1-2017005 · Cited by 16
Gut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
Metformin and its redox-related mechanisms of action in type 2 diabetes
Vezza, T., Luna-Marco, C., Rovira‐Llopis, S., & Víctor, V. M. (2023) · Redox Experimental Medicine · doi:10.1530/rem-23-0015 · Cited by 8
Xie, Z., Chen, Z., & Chen, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119207 · Cited by 8
Jacenik, D., Lebish, E. J., & Beswick, E. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113561 · Cited by 8
Neonatal Pig Liver–Derived Progenitors for Insulin-Producing Cells: An In Vitro Study
Racanicchi, L., Basta, G., Montanucci, P., Guido, L. G., Pensato, A., Conti, V., & Calafiore, R. (2007) · Tissue Engineering · doi:10.1089/ten.2007.0098 · Cited by 9
From Beta Cell Replacement to Beta Cell Regeneration: Implications for Antidiabetic Therapy
Liu, C., & Wu, H. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814540611 · Cited by 10
Influence of gestational age on serum incretin levels in preterm infants
Shoji, H., Watanabe, A., Ikeda, N., Mori, M., Kitamura, T., Hisata, K., & Shimizu, T. (2016) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174416000404 · Cited by 9
Acute effect of an amino acid mixture in the rat glycemic profile
Pena, M. J., Guerreiro, S. G., Rocha, J. C., Morais, T., Pereira, S. S., Monteiro, M. P., & Borges, N. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28576 · Cited by 11
“Besides the incretin effect, GLP‐1 was shown to promote insulin synthesis by pancreatic islets, to increase β‐cell glucose sensitivity and to stimulate proliferation while inhibiting β‐cell apoptosis in rodent models.(18,19) Apart from the pancreas, several other tissues were demonstrated to express GLP‐1 receptors, i…”
BackgroundThe PI3K/Akt1-FoxO1 Translocation Pathway Mediates EXf Effects on NIT-1 Cell Survival
Hou, G., Li, C.-N., Huan, Y., Liu, S., Liu, Q., Liu, M., & Shen, Z. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-117048 · Cited by 8
Fontana, J., Kučera, O., Mezera, V., Anděl, M., & Červinková, Z. (2017) · Physiological Research · doi:10.33549/physiolres.933464 · Cited by 8
“…modulation of liver functions and liver lipid metabolism by their action (supported by proliferative and antiapoptotic effects of GLP-1 on various tissues, e.g. pancreatic β-cells) (Farilla et al. 2002), data regarding their potential effect on liver regeneration are missing in literature.”
BackgroundMonazzam, A., Lau, J., Velikyan, I., Li, S., Razmara, M., Rosenström, U., Eriksson, O., & Skogseid, B. M. (2018) · Scientific Reports · doi:10.1038/s41598-017-18855-0 · Cited by 8
Uhles, S., Wang, H., Benardeau, A. M., Prummer, M., Brecheisen, M., Sewing, S., Tobalina, L., Bosco, D., Wollheim, C. B., Migliorini, C., et al. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01352.x · Cited by 9
Clough, T. J., Baxan, N., Coakley, E. J., Rivas, C., Zhao, L., Leclerc, I., Martínez-Sánchez, A., Rutter, G. A., & Long, N. J. (2020) · Dalton Transactions · doi:10.1039/d0dt00332h · Cited by 8
Nugraheni, M., Purwanti, S., & Ekawatiningsih, P. (2021) · Preventive Nutrition and Food Science · doi:10.3746/pnf.2021.26.3.296 · Cited by 8
“…types of analog rice used in this study contained resistant starch that can lower insulin resistance, pancreatic β-cell mass, increase glucagon-like peptide-1 (GLP-1) production to mediate glucose-dependent insulin secretion and increase insulin levels (Farilla et al., 2002; Shen et al., 2011).”
BackgroundIncretins in the Therapy of Diabetic Kidney Disease
Przezak, A., Bielka, W., & Pawlik, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212312 · Cited by 7
“Acting through pancreatic GLP1Rs, GLP1 potentiates insulin secretion induced by glucose, as well as promoting growth and inhibiting the apoptosis of β-cells [1,18,19].”
Control of liver glucokinase activity: A potential new target for incretin hormones?
Francini, F., Massa, M. L., Polo, M. P., Villagarcía, H. G., Castro, M. C., & Gagliardino, J. J. (2015) · Peptides · doi:10.1016/j.peptides.2015.10.006 · Cited by 7
In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetes
Skarbaliene, J., Rigbolt, K. T. G., Fosgerau, K., & Billestrup, N. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.026 · Cited by 7
“Studies in isolated human islets and in rodent models of T2D have shown anti-apoptotic, regenerative, and functional improvement effects on β-cells after treatment with GLP-1 agonists (Farilla et al., 2002, 2003; Kwon et al., 2009; Xu et al., 1999).”
BackgroundÅhrén, B. (2009) · Insulin · doi:10.1016/s1557-0843(09)80004-3 · Cited by 7
Zukünftige Angriffspunkte für die Therapie des Typ-2-Diabetes
Stingl, H., & Roden, M. (2004) · Wiener klinische Wochenschrift · doi:10.1007/bf03041051 · Cited by 7
The Evidence for Achieving Glycemic Control With Incretin Mimetics
Drucker, D. J. (2006) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706287652 · Cited by 7
“GLP-1 also improves β-cell function in animal models and in human islets studied in vitro.(22,23) Accordingly, incretin-based therapies show great promise for the treatment of type 2 diabetes.”
BackgroundImproving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
Freeman, J. S. (2012) · PubMed · Cited by 7
Chemical Strategies for Improving Islet Transplant Outcomes
Quintana, J. M., Stinchcomb, A. L., Kostyo, J. H., Robichaud, B., Plunk, M. A., & Kane, R. R. (2018) · OBM Transplantation · doi:10.21926/obm.transplant.1804036 · Cited by 7
Glucagon like peptide-1: A new therapeutic target for diabetes mellitus
Patel, S., Goyal, R., Anand, I., Shah, J., Patel, H., & Patel, C. (2006) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.27018 · Cited by 7
“and db/db mice with an associated increase in the islet size and β-cell mass.([40-42]) In addition, GLP-1 also protects against”
BackgroundGao, H., Zhao, Q., Tang, S., Li, K., Qin, F., Song, Z., Pan, Y., Jin, L., & Zhang, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-83201-4 · Cited by 5
Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function
Welters, A., & Lammert, E. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_474 · Cited by 5
Rasalam, R. R., Abdo, S., Deed, G., O’Brien, R. C., & Overland, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14953 · Cited by 7
Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist
Naver, S. V., Jimenez‐Solem, E., Christensen, M., Andersen, J. T., & Knop, F. K. (2014) · Clinical Investigation · doi:10.4155/cli.14.65 · Cited by 6
Sakata, S., Ito, M., Mera, Y., Sasase, T., Yamamoto, H., Kakutani, M., & Ohta, T. (2014) · Journal of Diabetes Research · doi:10.1155/2014/803832 · Cited by 7
“In addition, GLP-1 is known to be able to prevent apoptosis in the pancreatic β cell and stimulate the proliferation and differentiation of insulin-secretingβ cells in ZDF rats [20, 21].”
Insulin as a First-Line Therapy in Type 2 Diabetes
Standl, E., & Schnell, O. (2008) · Diabetes Care · doi:10.2337/dc08-s234 · Cited by 5
“-Cell mass seems to be best preserved with DPP-IV inhibitors and GLP1-analogs in animal studies (17,18).”
BackgroundAdvances in Diabetes Therapy in the Elderly
Lee, F. (2009) · Journal of Pharmacy Practice and Research · doi:10.1002/j.2055-2335.2009.tb00707.x · Cited by 5
Growth Factor Mediated Regulation of Beta Cell Survival
Vasavada, R. C. (2010) · The Open Endocrinology Journal · doi:10.2174/1874216501004010078 · Cited by 6
The role of GLP-1 in the regulation of islet cell mass
Bulotta, A., Farilla, L., Hui, H., & Perfetti, R. (2004) · Cell Biochemistry and Biophysics · doi:10.1007/bf02739013 · Cited by 8
Self-citationNauck, M. A., Schmidt, W. E., & Meier, J. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_12 · Cited by 5
“In rodent models of diabetes, GLP-1 led to an increase in β-cell replication, a stimulation of islet neogenesis, and an inhibition of β-cell apoptosis [199–203].”
BackgroundGupta, P., & Ekbbal, R. (2023) · Current Drug Research Reviews · doi:10.2174/0125899775243787231103075804 · Cited by 5
Ruggeri, R. M., Grossrubatscher, E. M., Ciocca, E., Hasballa, I., Jaafar, S., Oldani, M., Rubino, M., Russo, F., Isidori, A. M., Colao, A. A. L., et al. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09958-5 · Cited by 5
“…and old (22 months) Wistar rats GLP-1 GLP-1 induces pancreatic cell proliferation and β-cell differentiation through up-regulation of Pdx1 expression Farilla et al. (2002) [29] Zucker diabetic rats GLP-1 GLP-1 provides an increase in islet cell proliferation and a decrease of cellular apoptosis…”
A New Therapy of Type 2 Diabetes: DPP-4 Inhibitors
Ábel, T. (2011) · InTech eBooks · doi:10.5772/23604 · Cited by 4
Metadata
- Authors
- Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R.
- Affiliations
- Cedars-Sinai Medical Center (US)
- University of California, Los Angeles (US)
- Corresponding author
- Perfetti, Riccardo
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2002-11-01
- Volume
- 143
- Issue
- 11
- Pages
- 4397-4408
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2063693981
- Cited by
- 502
- References
- 20
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 10 · 2022: 5 · 2021: 17 · 2020: 12 · 2019: 18 · 2018: 12 · 2017: 16 · 2016: 18 · 2015: 25 · 2014: 32 · 2013: 33 · 2012: 33
- FWCI
- 17.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Federation for Aging Research
- Cedars-Sinai Medical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- glucagon-like peptide-1, islet cell proliferation, beta-cell apoptosis, type 2 diabetes, insulin secretion, glucose tolerance, caspase-3, Ki-67, exocrine pancreas, pancreatic islets, nuclear fragmentation
- MeSH terms
- Insulin Secretion, Animals, Blood Glucose, Cell Division, Diabetes Mellitus, Glucagon, Insulin, Islets of Langerhans, Kinetics, Male, Peptide Fragments, Protein Precursors, Rats, Zucker, Apoptosis, Ki-67 Antigen, Caspases, In Situ Nick-End Labeling, Rats, Glucagon-Like Peptide 1, Caspase 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.